These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1987751)

  • 1. Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit.
    Lloveras B; Edgerton S; Thor AD
    Am J Clin Pathol; 1991 Jan; 95(1):41-7. PubMed ID: 1987751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma.
    Meyer JS; Koehm SL; Hughes JM; Higa E; Wittliff JL; Lagos JA; Manes JL
    Cancer; 1993 Jun; 71(11):3531-40. PubMed ID: 8490901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
    Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H
    Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology and behavior of small breast carcinomas.
    Meyer JS; Fahrner M; Daniel FC
    Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
    Thor AD; Liu S; Moore DH; Edgerton SM
    J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade.
    Weidner N; Moore DH; Ljung BM; Waldman FM; Goodson WH; Mayall B; Chew K; Smith HS
    Am J Surg Pathol; 1993 Oct; 17(10):987-94. PubMed ID: 8372950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.
    Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD
    AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-phase fractions of breast carcinomas. Relationships to morphology, estrogen and progesterone receptors, and early recurrence.
    Meyer JS; Bauer WC; Stevens SC; Rao BR; White WL
    Bull Cancer; 1978; 65(4):449-54. PubMed ID: 747801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
    Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
    Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
    Keshgegian AA
    Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling.
    Meyer JS; Nauert J; Koehm S; Hughes J
    J Histochem Cytochem; 1989 Sep; 37(9):1449-54. PubMed ID: 2768814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.